Evidence map›Paper›PMID 39420342›Full record

ArticleCell communication and signaling : CCS2024

Acetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1

Wenchang Zhou, Mengdi Qu, Ying Yue, Ziwen Zhong, Ke Nan, Xingfeng Sun, Qichao Wu, Jie Zhang, Wankun Chen, Changhong Miao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell communication and signaling : CCS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Redefining the role of the thiol-based agentRSC medicinal chemistry · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenchang Zhou *Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Mengdi Qu *Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Ying YueDepartment of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Ziwen ZhongDepartment of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Ke NanDepartment of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Xingfeng SunDepartment of Anesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200438, China.
Qichao WuDepartment of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Jie ZhangDepartment of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Wankun ChenDepartment of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China. chen.wankun@zs-hospital.sh.can.
Changhong MiaoDepartment of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China. miao.changhong@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProgrammed cell death protein 1 (PD-1) blockade is essential in treating progressive colorectal cancer (CRC). However, some patients with CRC do not respond well to immunotherapy, possibly due to the exhaustion of CD8

methodsWe constructed a mouse CRC model to study the effect of NAC on tumors. The effect of NAC on CD8 + T cell differentiation and its potential mechanism were explored using cell flow assay and other studies in vitro and ex vivo.

resultsWe demonstrated that NAC synergized PD-1 antibodies to inhibit CRC progression in a mouse CRC model mediated by CD8

conclusionsOur study provides a novel idea for immunotherapy for clinically progressive CRC and suggests that Glut4 may be a new immunometabolic molecular target for regulating CD8

Indexed as

AcetylcysteineCD8-Positive T-LymphocytesCell DifferentiationColorectal NeoplasmsDisease ProgressionHepatocyte Nuclear Factor 1-alphaProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorDrug SynergismHumansImmune Checkpoint InhibitorsMiceMice, Inbred C57BLAcetylcysteineHepatocyte Nuclear Factor 1-alphaHnf1a protein, mouseImmune Checkpoint InhibitorsPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorAcetylcysteineCD8+ T lymphocytesColorectal cancerGlucose transporter 4PD-1 blockade

Identifiers

PMID39420342
PMCPMC11484120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.